Please go to the PowerPak homepage
and select a course.
Omega-3 Fatty Acids and ASCVD
This activity is sponsored by Postgraduate Healthcare Education, LLC and Medtelligence and has been supported by an educational grant from Amarin Pharma, Inc.
Dave L. Dixon, PharmD, FACC, FCCP, FNLA, BCPS, BCACP, CDE, CLS (Chair)
Associate Professor and Vice-Chair of Clinical Services
Department of Pharmacotherapy & Outcomes Science
Director, Center for Pharmacy Practice Innovation
Virginia Commonwealth University School of Pharmacy
Daniel E. Hilleman, PharmD, FCCP
Professor and Director, Continuing Education
Creighton University School of Pharmacy and Health Professions
Joseph Saseen, PharmD, BCPS, BCACP, CLS
Professor and Vice Chair, Clinical and Academic Programs; Department of Clinical Pharmacy
Professor; Department of Family Medicine
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Dr. Dixon and Dr. Saseen hereby state that they do not have relevant affiliation or financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose. Dr. Hilleman discloses the following: Speaker’s Bureau-Amarin and Consultant (e.g. Advisory Board)-Heron Therapeutics.
The following reviewer, Ben Caref, PhD. states that he has no financial relationship or relationship to products or devices with a commercial interest related to the content of this activity to disclose.
Susanne Batesko, RN, BSN, and Robin Carrino, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Credits: 0.75 hour (0.75 ceu)
Type of Activity: Knowledge
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 45 minutes
June 18, 2020
June 18, 2021
This activity is designed to meet the educational needs of retail, hospital and managed care pharmacists.
HOW TO EARN CREDIT
During the period June 18, 2020 to June 18, 2021, participants must 1) read the learning objectives and faculty disclosures; 2) view the
educational activity; and 3) complete the posttest and evaluation form
directly after the activity within a maximum of 60 days of participating
in the activity. To answer the questions, click on your selected choice
for each answer then proceed to the next question. Once completed,
click on the Grade Exam button at the bottom of the page. Your posttest
will automatically be graded. If you successfully complete the posttest
(score of 75% or higher), your statement of participation will be made
available immediately. Click on the View Statement of Participation link
and print the statement for your records. If you receive a score lower
than 75%, you will receive a message notifying you that you did not pass
the posttest. You will have 2 opportunities to pass the posttest. To
receive Credit, you must provide your date of birth and NABP number. All
Credit information will be uploaded into CPE monitor within 30 days.
During this interactive and engaging activity, we will focus on addressing the role of omega-3 fatty acids in treating patients with or at high risk of atherosclerotic cardiovascular disease (ASCVD) using the most recent evidence and guideline recommendations.
At the conclusion of this activity, learners should be better able to:
- Describe the spectrum of large-scale omega-3 fatty acids on ASCVD outcomes trials
- Recognize the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
- Review information on clinical utility of adjuncts to statin therapy to improve management of patients with or at high risk of ASCVD events
» Slides (PDF) | » Transcript (PDF)
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer:
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, Medtelligence and Amarin Pharma, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without an evaluation of their patients’ conditions and current medications, including the identification of possible contraindications regarding the dangers of use and a review of any applicable manufacturer’s product information, as well as a comparison with the recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer’s package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA. Nutritional products discussed are not intended for the diagnosis, treatment, cure, or prevention of any disease.